What is Tesofensine?
Tesofensine is a research compound originally developed to treat neurodegenerative diseases like Parkinson's and Alzheimer's. It didn't work well for those conditions — but researchers noticed something unexpected: people taking it lost a significant amount of weight.[1] That accidental discovery sent scientists down a new path, studying tesofensine as a potential obesity treatment. It belongs to a class called triple monoamine reuptake inhibitors — a mouthful, but the idea is fairly simple once you understand how it works.
How Tesofensine Works
Think of your brain's chemical messengers — dopamine, norepinephrine (also called noradrenaline), and serotonin — as taxis dropping off passengers at busy street corners. Normally, after a taxi drops someone off, it loops back to pick up more fares (a process called "reuptake"). Tesofensine blocks that loop. It stops all three of these chemical taxis from returning, so the messengers linger longer at their destinations.[1]
What does that do in practice? Inside the brain, longer-lasting dopamine and norepinephrine signals appear to suppress appetite. Research in diet-induced obese rats pinned down the mechanism further: tesofensine's hunger-reducing effect works mainly through alpha-1 adrenoceptors (a type of norepinephrine receptor) and dopamine D1 receptors. When scientists blocked those receptors, most of tesofensine's appetite-suppressing power disappeared.[6]
There's also a fascinating brain-circuit angle. A 2024 study used advanced tools — including optogenetics (controlling neurons with light) and electrophysiology (recording electrical signals in the brain) — to show that tesofensine silences a specific group of neurons in the lateral hypothalamus, a region that controls feeding. These are GABAergic neurons — cells that normally promote eating. By quieting them, tesofensine reduces the urge to eat.[2] The same study found that tesofensine also blocked the body-weight rebound that often follows weight loss — a promising finding, since regaining lost weight is one of the biggest challenges in obesity management.[2]
What the Research Shows
The most talked-about clinical findings came from a phase II trial in obese patients. Over 14 weeks, participants taking tesofensine showed dose-related reductions in body weight, body fat, and waist circumference — along with improvements in other hormones linked to obesity.[1] Researchers commenting in The Lancet noted both the promise of these results and the importance of watching cardiovascular signals carefully.[3][4]
Before the obesity trials began, an earlier set of studies looked back at data from the Parkinson's and Alzheimer's disease trials. A meta-analysis of four randomized, double-blind trials — covering nearly 1,000 patients — found that tesofensine produced a placebo-subtracted weight loss of roughly 4% over 14 weeks, even without any diet or lifestyle program. Among obese participants, up to 32% of those on the highest dose achieved at least 5% body-weight loss, compared to just 2% on placebo. Heart rate did increase slightly in a dose-dependent way, but blood pressure showed no significant change in this cohort.[5]
In rat studies, tesofensine not only reduced food intake sharply but also appeared to normalize dopamine signaling that had been disrupted by a high-fat diet.[6] Compared to phentermine — a common appetite suppressant — tesofensine caused far fewer stereotyped, repetitive movements (like head-weaving), suggesting a potentially cleaner side-effect profile at research doses.[2]
What Tesofensine Is Being Studied For
- Obesity and weight loss — the primary research focus, backed by both human clinical trials and animal studies[1]
- Appetite suppression — specifically the brain pathways that drive overeating[6]
- Glycemic improvement — animal research suggests benefits for blood-sugar control alongside weight loss[6]
- Preventing weight regain — early evidence that it may block the rebound effect after dieting[2]
- Neurodegenerative disease — the original application; weight loss was an incidental finding in these trials[5]
How Tesofensine Is Dosed in Research
Doses used in studies have varied quite a bit depending on the research question — ranging from fractions of a milligram in human trials to a few milligrams per kilogram in rat models. Human phase II trials tested daily oral doses, while animal studies used subcutaneous (under-the-skin) injections. Because the right amount depends entirely on the experimental context, we've laid out every documented research dose in the dosage chart on this page. If you need to scale or convert a dose for your own research protocol, the calculator on this page can help you work through the numbers.
Mixing and Storing Tesofensine
Tesofensine for research use typically arrives as a dry powder or a pre-made solution, depending on the supplier. If you're working with a lyophilized (freeze-dried) powder, you'll need to reconstitute it — that means dissolving it in a suitable solvent. Sterile water, bacteriostatic water, or a DMSO-and-water mixture are commonly used, depending on the solubility requirements specified by your supplier. Always add solvent slowly and swirl gently rather than shaking, to avoid foaming. Once mixed, store the solution in a sealed vial in the refrigerator (2–8 °C) and protect it from light. If you're not using it within a few days, aliquoting (splitting it into small single-use portions) and freezing at –20 °C helps preserve stability. Label every vial clearly with the concentration, date of reconstitution, and solvent used. Never use a solution that looks cloudy or discolored.
Sources
- Tesofensine, a monoamine reuptake inhibitor for the treatment of obesity. — Current opinion in investigational drugs (London, England : 2000), 2009. PMID 19777399.
- Tesofensine, a novel antiobesity drug, silences GABAergic hypothalamic neurons. — PloS one, 2024. PMID 38656972.
- Tesofensine and weight loss. — Lancet (London, England), 2009. PMID 19249626.
- Tesofensine and weight loss. — Lancet (London, England), 2009. PMID 19249625.
- Weight loss produced by tesofensine in patients with Parkinson's or Alzheimer's disease. — Obesity (Silver Spring, Md.), 2008. PMID 18356831.
- Tesofensine, a novel triple monoamine reuptake inhibitor, induces appetite suppression by indirect stimulation of alpha1 adrenoceptor and dopamine D1 receptor pathways in the diet-induced obese rat. — Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2010. PMID 20200509.
EN
BR
ES
FR
DE
RU